Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
BACK TO LIST

Laboratory Report

Patient
Name: Gaičiūnas, , Gabrielius,
DOB: 19-MAY-1948 (Age: 77)
Gender: male
Address:
5951 Monika Rapid
97190 Poškaton (Lithuania)
ID: 5711-320329-3 (ECI)
Report
Date: 22-SEP-2017
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Dr. Tomas Bakas
182 Savanorių pr.
LT-91200 Klaipėda (Lithuania)
Specimen
Collected: 22-SEP-2017

Chemistry

Test 22-SEP-2017 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 4.0 L 4.6 - 6.4 %
Glucose [Mass/volume] in Blood 95.9 70 - 110 mg/dL
Urea nitrogen [Mass/volume] in Blood 19.7 7 - 43 mg/dL
Creatinine [Mass/volume] in Blood 0.9 0.9 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 8.8 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 137.6 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.3 3.5 - 5.3 mmol/L
Chloride [Moles/volume] in Blood 101.3 98 - 108 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 25.3 22 - 29 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 221.7 H 0 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 106.0 0 - 199 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 170.7 H 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 29.8 L 40 - 100 mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows low HbA1c, likely reflecting absence of diabetes or possible hypoglycemia. Renal and electrolyte parameters are within normal limits. Lipid profile reveals elevated total and LDL cholesterol and low HDL cholesterol, indicating increased cardiovascular risk. Recommend clinical correlation and consideration of lipid-lowering therapy and lifestyle modification.